Abstract:(1) Background: Health-related quality of life (HRQoL) gains importance as novel treatment options for individuals with esophagogastric tumors to improve long-term survival. Impaired HRQoL has been shown to be a predictor of overall survival. Sarcopenia is a known prognostic factor for postoperative complications. As the regular control of sarcopenia through CT scans might not always be possible and HRQoL and nutritional scores are easier to obtain, this study aimed to assess the relationship between nutritional scores, HRQoL and skeletal muscle mass in patients undergoing chemotherapy for cancers of the upper gastrointestinal tract. (2) Methods: Eighty patients presenting with tumors of the upper GI tract were included and asked to fill out the standardized HRQoL questionnaire, EORTC's QLQ-C30. Nutritional status was assessed using the MNA, MUST and NRS 2002 scores. Sarcopenia was determined semi-automatically based on the skeletal muscle index at the L3 vertebrae level in staging CT scans. (3) Results: In chemo-naïve patients, HRQoL summary scores correlated significantly with nutritional scores and SMI. SMI and HRQoL prior to neoadjuvant therapy correlated significantly with SMI after treatment. (4) Conclusions: HRQoL is a helpful tool for assessing patients' overall constitution. The correlation of HRQoL summary scores and SMI might allow for a rough assessment of skeletal muscle status through HRQoL assessment in chemo-naïve patients.

What problem does this paper attempt to address?

The paper attempts to address the issue of exploring the relationship between health-related quality of life (HRQoL), nutritional status, and skeletal muscle mass in patients with esophagogastric tumors before and after neoadjuvant therapy. Specifically, the study aims to evaluate the changes in these parameters before and after chemotherapy and their interrelationships, with the goal of predicting patients' muscle mass and nutritional status through simple HRQoL assessments, thereby providing support for clinical decision-making. ### Main Issues: 1. **The relationship between HRQoL, nutritional status, and skeletal muscle mass**: The study explores the correlation of these parameters before and after chemotherapy, particularly whether HRQoL can serve as an indicator for assessing muscle mass and nutritional status. 2. **The impact of chemotherapy on these parameters**: The study analyzes the changes in these parameters before and after chemotherapy to understand the impact of chemotherapy on the overall health status of patients. 3. **Potential value for clinical application**: The study aims to provide clinicians with a simple method to quickly understand patients' muscle mass and nutritional status through HRQoL assessments, thereby optimizing treatment plans. ### Research Background: - Patients with esophagogastric tumors often experience a decline in quality of life, malnutrition, and muscle loss (i.e., sarcopenia) due to the tumor itself and subsequent treatments. - Sarcopenia and malnutrition not only affect patients' treatment tolerance and survival rates but may also lead to postoperative complications. - Traditional CT scan assessments of sarcopenia are relatively complex, while HRQoL assessments are relatively simple and easy to implement. ### Research Methods: - **Study Design**: This is a cross-sectional study including 80 patients with esophagogastric tumors, divided into two groups: pre-chemotherapy (t1 group) and post-chemotherapy (t2 group). - **Data Collection**: HRQoL was assessed using the EORTC QLQ-C30 questionnaire, nutritional status was assessed using MNA, MUST, and NRS 2002 scores, and skeletal muscle index (SMI) was measured through CT scans. - **Statistical Analysis**: Spearman correlation coefficients were used to analyze the correlations between HRQoL, nutritional scores, and SMI. ### Main Findings: - **Pre-chemotherapy**: HRQoL scores were significantly correlated with nutritional scores and SMI, indicating an association between these parameters at initial diagnosis. - **Post-chemotherapy**: The correlation between HRQoL scores and SMI weakened but remained significantly correlated with physical function and global quality of life scores. - **Changes in SMI**: There was little change in SMI before and after chemotherapy, but pre-chemotherapy SMI was significantly correlated with post-chemotherapy SMI. ### Conclusion: - HRQoL is a useful tool for assessing patients' overall health status. - The correlation between pre-chemotherapy HRQoL scores and SMI may allow for a rough estimation of muscle mass through HRQoL assessments. - These findings support the comprehensive assessment of skeletal muscle function and quality in clinical practice, rather than solely quantitative SMI assessments. Through these research results, clinicians can better understand patients' health status and make more precise decisions during the treatment process.

Quality of Life, Sarcopenia and Nutritional Status in Patients with Esophagogastric Tumors before and after Neoadjuvant Therapy

Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer

The additional benefit of computed tomography in cancer patients: impacts of sarcopenia and cachexia on quality of life during chemotherapy

Prospective Evaluation of Sarcopenia in Head and Neck Cancer Patients Treated with Radiotherapy or Radiochemotherapy

Prognostic Impact of Sarcopenia in Patients with Locally Advanced Adenocarcinoma of the Esophagogastric Junction Treated with Neoadjuvant Chemoradiotherapy

Sarcopenia is a Predictive Factor of Poor Quality of Life and Prognosis in Patients after Radical Gastrectomy

Associations between skeletal muscle mass index, nutritional and functional status of patients with oesophago-gastric cancer

Impact of Skeletal Muscle Loss after Adjuvant Chemoradiotherapy in Patients with Gastric Cancer.

Clinical Impact of Sarcopenia on Gastric Cancer and the Effect of Neoadjuvant Chemotherapy on Sarcopenia

Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment

Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation

Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy

Chemotherapy-Related Toxicity, Nutritional Status and Quality of Life in Precachectic Oncologic Patients with, or without, High Protein Nutritional Support. A Prospective, Randomized Study

Prevalence and clinical outcomes of sarcopenia in patients with esophageal, gastric or colorectal cancers receiving preoperative neoadjuvant therapy: A meta-analysis

Relationship Between Sarcopenia and Prognosis in Patient With Concurrent Chemo-Radiation Therapy for Esophageal Cancer

Skeletal Muscle Change During Neoadjuvant Therapy and Its Impact on Prognosis in Patients With Gastrointestinal Cancers: A Systematic Review and Meta-Analysis

Evaluation of nutritional parameters that may be associated with survival in patients with locally advanced non-small cell lung carcinoma receiving definitive concurrent chemoradiotherapy: retrospective study conducted in a tertiary pulmonary hospital

Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis

A Combination of Preoperative Computed Tomography-Defined Sarcopenia and Systemic Inflammation on Survival in Patients with Poorly Differentiated Neuroendocrine Neoplasms Following Radical Resection

Role of Nutritional Status in the Treatment Outcome for Esophageal Squamous Cell Carcinoma

Nutritional Status And Quality Of Life In Patients With Gastric Cancer In China.